肽聚糖合成的其他抗生素抑制剂。
Additional antibiotic inhibitors of peptidoglycan synthesis.
作者信息
Linnett P E, Strominger J L
出版信息
Antimicrob Agents Chemother. 1973 Sep;4(3):231-6. doi: 10.1128/AAC.4.3.231.
Abstract
Diumycin, janiemycin, nisin, and subtilin inhibited peptidoglycan synthesis catalyzed by particulate enzyme systems from Bacillus stearothermophilus and Escherichia coli. All of these, except for nisin, also induced accumulation of the lipid intermediate in peptidoglycan synthesis. Concentrations required for 50% inhibition of peptidoglycan synthesis were less than 0.1 mug/ml for diumycin and in the range of 10 to 100 mug/ml for janiemycin, nisin, and subtilin in both organisms. The discrepancy between the extremely low concentration of diumycin required to inhibit the in vitro system from E. coli and the much higher concentration required to inhibit growth of the organism is noteworthy.
摘要
迪尤霉素、杰尼霉素、乳链菌肽和枯草菌素抑制了嗜热脂肪芽孢杆菌和大肠杆菌的颗粒酶系统催化的肽聚糖合成。除乳链菌肽外，所有这些物质还诱导了肽聚糖合成中脂质中间体的积累。在两种生物体中，抑制肽聚糖合成50%所需的浓度，迪尤霉素小于0.1微克/毫升，杰尼霉素、乳链菌肽和枯草菌素在10至100微克/毫升范围内。抑制大肠杆菌体外系统所需的迪尤霉素浓度极低，而抑制该生物体生长所需的浓度则高得多，这种差异值得注意。
相似文献
1
Additional antibiotic inhibitors of peptidoglycan synthesis.
Antimicrob Agents Chemother. 1973 Sep;4(3):231-6. doi: 10.1128/AAC.4.3.231.
2
Gardimycin, a new antibiotic inhibiting peptidoglycan synthesis.
Antimicrob Agents Chemother. 1977 Mar;11(3):396-401. doi: 10.1128/AAC.11.3.396.
3
Inhibition of peptidoglycan synthesis by the antibiotic diumycin A.
Antimicrob Agents Chemother. 1972 Dec;2(6):485-91. doi: 10.1128/AAC.2.6.485.
4
Inhibition of cell wall synthesis by the antibiotics diumycin and janiemycin.
Ann N Y Acad Sci. 1974 May 10;235(0):399-405. doi: 10.1111/j.1749-6632.1974.tb43279.x.
5
Inhibition of in vitro peptidoglycan biosynthesis in Escherichia coli by guanosine 5'-diphosphate 3'-diphosphate.
Can J Microbiol. 1980 Dec;26(12):1514-8. doi: 10.1139/m80-253.
6
The site of inhibition of bacterial cell wall peptidoglycan synthesis by azureomycin B, a new antibiotic.
J Biochem. 1980 Aug;88(2):565-70. doi: 10.1093/oxfordjournals.jbchem.a133004.
7
Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity.
J Biol Chem. 2001 Jan 19;276(3):1772-9. doi: 10.1074/jbc.M006770200. Epub 2000 Oct 18.
8
In vivo and in vitro action of new antibiotics interfering with the utilization of N-acetyl-glucosamine-N-acetyl-muramyl-pentapeptide.
J Bacteriol. 1971 Oct;108(1):20-9. doi: 10.1128/jb.108.1.20-29.1971.
9
Role of the leader and structural regions of prelantibiotic peptides as assessed by expressing nisin-subtilin chimeras in Bacillus subtilis 168, and characterization of their physical, chemical, and antimicrobial properties.
J Biol Chem. 1995 Oct 6;270(40):23533-9. doi: 10.1074/jbc.270.40.23533.
10
Synthesis of peptidoglycan by high molecular weight penicillin-binding proteins of Bacillus subtilis and Bacillus stearothermophilus.
J Biol Chem. 1984 Feb 10;259(3):1483-90.
引用本文的文献
1
Mechanisms of action of ribosomally synthesized and posttranslationally modified peptides (RiPPs).
J Ind Microbiol Biotechnol. 2021 Jun 4;48(3-4). doi: 10.1093/jimb/kuab005.
2
Lantibiotics Produced by Oral Inhabitants as a Trigger for Dysbiosis of Human Intestinal Microbiota.
Int J Mol Sci. 2021 Mar 25;22(7):3343. doi: 10.3390/ijms22073343.
3
Targeting the Achilles' Heel of Bacteria: Different Mechanisms To Break Down the Peptidoglycan Cell Wall during Bacterial Warfare.
J Bacteriol. 2021 Mar 8;203(7). doi: 10.1128/JB.00478-20.
4
Overview of the Antimicrobial Compounds Produced by Members of the Group.
Front Microbiol. 2019 Feb 26;10:302. doi: 10.3389/fmicb.2019.00302. eCollection 2019.
5
Cell envelope stress response in cell wall-deficient L-forms of Bacillus subtilis.
Antimicrob Agents Chemother. 2012 Nov;56(11):5907-15. doi: 10.1128/AAC.00770-12. Epub 2012 Sep 10.
6
Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics.
Curr Opin Microbiol. 2008 Oct;11(5):401-8. doi: 10.1016/j.mib.2008.09.008. Epub 2008 Oct 24.
7
Molecular mechanism of target recognition by subtilin, a class I lanthionine antibiotic.
Antimicrob Agents Chemother. 2008 Feb;52(2):612-8. doi: 10.1128/AAC.00836-07. Epub 2007 Nov 12.
8
Alanine scan of [L-Dap(2)]ramoplanin A2 aglycon: assessment of the importance of each residue.
J Am Chem Soc. 2007 Jul 18;129(28):8747-55. doi: 10.1021/ja068573k. Epub 2007 Jun 26.
9
Lipid II-mediated pore formation by the peptide antibiotic nisin: a black lipid membrane study.
J Bacteriol. 2004 May;186(10):3259-61. doi: 10.1128/JB.186.10.3259-3261.2004.
10
Bacteriocins of gram-positive bacteria.
Microbiol Rev. 1995 Jun;59(2):171-200. doi: 10.1128/mr.59.2.171-200.1995.
本文引用的文献
1
Bacitracin: an inhibitor of the dephosphorylation of lipid pyrophosphate, an intermediate in the biosynthesis of the peptidoglycan of bacterial cell walls.
Proc Natl Acad Sci U S A. 1967 Mar;57(3):767-73. doi: 10.1073/pnas.57.3.767.
2
3
Meonomycin, a new antibiotic. II. Characterization and chemistry.
Antimicrob Agents Chemother (Bethesda). 1965;5:737-42.
4
Moenomycin, a new antibiotic. I. Fermentation and isolation.
Antimicrob Agents Chemother (Bethesda). 1965;5:734-6.
5
[STRUCTURE ELUCIDATION OF THE LIPID PORTION OF MOENOMYCIN].
Justus Liebigs Ann Chem. 1969;720:58-70. doi: 10.1002/jlac.19687200105.
6
Specificity of combination between mucopeptide precursors and vancomycin or ristocetin.
Biochem J. 1969 Jan;111(2):195-205. doi: 10.1042/bj1110195.
7
Enduracidin, an inhibitor of cell wall synthesis.
J Antibiot (Tokyo). 1968 Jun;21(6):426-8. doi: 10.7164/antibiotics.21.426.
8
Molecular association of the antibiotic prasinomycins.
J Pharm Sci. 1968 Apr;57(4):690-3. doi: 10.1002/jps.2600570434.
9
Mode of action of prasinomycin.
Antimicrob Agents Chemother (Bethesda). 1967;7:251-6.
10
Chemistry of enduracidins, new antibiotics.
Antimicrob Agents Chemother (Bethesda). 1970;10:6-11.
Zotero 插件